Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Dr. McFarland Granted Patent for Oral Hygeine Device
View:
Post by Eoganacht on Oct 15, 2021 8:34am

Dr. McFarland Granted Patent for Oral Hygeine Device

Oral hygiene device Patent No. D932023 Inventor(s): Colin G. Cameron (Haslet, TX), Sherri McFarland (Haslet, TX) Assignee(s): PhotoDynamic Inc. (Halifax, , CA) Law Firm: Riverside Law LLP (5 non-local offices) Application No., Date, Speed: 29706480 on 09/20/2019 (739 days app to issue) Abstract: No Abstract Patent Class: N/A
Comment by Pandora on Oct 15, 2021 10:24am
This patent is for a device to go along with the USPTO patent 10925917 that was approved on February 23, 2021 for the Extracts/Agents. So I assume it is now a complete process for teeth cleaning. It will be interesting to see the commercialization. Invention title/Inventor Polygonum Cuspidatum Extracts As Photodynamic Inactivating Agents Sherri McFarland Patent 10925917 ...more  
Comment by Pandora on Oct 15, 2021 10:33am
This patent application is still pending: Invention title/Inventor ORAL HYGIENE SYSTEM AND METHOD OF USE Mark Tullio Morreale, Martin Labrecque, Sherri McFarland, Colin G. Cameron, Martin Greenwood, S. Alexander McLellan, Christopher David Gillespie Patent None Publication 20210085993 Mar 25, 2021 Application ...more  
Comment by Pandora on Oct 15, 2021 10:39am
As far as I know PhotoDynamic Inc. is a private company at this time. No idea if there is any intention for them to go public. https://www.photo-dynamic.com/
Theralase Technologies Inc.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT

Visit Facebook Visit X Visit Linked In Visit Instagram Visit Youtube



INVESTORS & MEDIA OVERVIEW FINANCIAL FILINGS PRESENTATIONS MEDIA FACT SHEETS MANAGEMENT

Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250